Intravenous Tranexamic Acid for Brain Contusion with Intraparenchymal Hemorrhage: Randomized, Double-Blind, Placebo-Controlled Trial

• Published in: Reviews on recent clinical trials Vol. 15; no. 1; p. 70
• Main Authors: Mousavinejad, Maryam, Mozafari, Javad, Ilkhchi, Reza Bahrami, Hanafi, Mohammad Ghasem, Ebrahimi, Pouya
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2020
• Subjects: Adult; Aged; Antifibrinolytic Agents - administration & dosage; Blood Loss, Surgical - prevention & control; Brain Contusion - complications; Brain Contusion - drug therapy; Brain Contusion - surgery; Brain Hemorrhage, Traumatic - etiology; Brain Hemorrhage, Traumatic - mortality; Brain Hemorrhage, Traumatic - prevention & control; Double-Blind Method; Female; Glasgow Coma Scale; Humans; Infusions, Intravenous; Male; Middle Aged; Survival Rate; Tranexamic Acid - administration & dosage; Treatment Outcome; trauma; intraparenchymal hemorrhage; linical trial study; emergency medicine; Cerebral hemorrhage; tranexamic acid
• ISSN: 1876-1038
• DOI: 10.2174/1574887114666191118111826

Controlling of secondary traumatic brain injuries (TBI) is necessary due to its salient effect on the improvement of patients with TBI and the final outcomes within early hours of trauma onset. This study aims to investigate the effect of intravenous tranexamic acid (TAX) administration on decreased hemorrhage during surgery. This double-blind, randomized, and placebo-controlled trial was conducted on patients referring to the emergency department (ED) with IPH due to brain contusion within 8 h of injury onset. The patients were evaluated by receiving TXA and 0.9% normal saline as a placebo. The following evaluation and estimations were performed: intracranial hemorrhage volume after surgery using brain CT-scan; hemoglobin (Hb) volume before, immediately after, and six hours after surgery; and the severity of TBI based on Glasgow Coma Score (GCS). 40 patients with 55.02 ± 18.64 years old diagnosed with a contusion and intraparenchymal hemorrhage. Although the (Mean ± SD) hemorrhage during surgery in patients receiving TXA (784.21 ± 304.162) was lower than the placebo group (805.26 ± 300.876), no significant difference was observed between two groups (P=0.83). The (Mean ± SD) Hb volume reduction immediately during surgery (0.07 ± 0.001 and 0.23 ± 0.02) and six hours after surgery (0.04 ± 0.008 and 0.12 ± 0.006) was also lower in TXA group but had no significant difference (P = 0.89 and P = 0.97, respectively). Using TXA may reduce the hemorrhage in patients with TBI, but this effect, as in this study, was not statistically significant and it is suggested that a clinical trial with a larger population is employed for further investigation.